Found: 6
Select item for more details and to access through your institution.
Healthcare costs and resource utilization in patients with migraine treated with erenumab: A retrospective, non‐interventional study using claims data from the United States.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 10, p. 1423, doi. 10.1111/head.14612
- By:
- Publication type:
- Article
Erenumab dosage for migraine prevention: An evidence‐based narrative review with recommendations.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 4, p. 420, doi. 10.1111/head.14266
- By:
- Publication type:
- Article
Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 9, p. 1411, doi. 10.1111/head.14208
- By:
- Publication type:
- Article
Pharmacovigilance: reporting requirements throughout a product's lifecycle.
- Published in:
- Therapeutic Advances in Drug Safety, 2022, v. 13, p. 1, doi. 10.1177/20420986221125006
- By:
- Publication type:
- Article
Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01238-2
- By:
- Publication type:
- Article
Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study.
- Published in:
- Cephalalgia Reports, 2021, v. 4, p. 1, doi. 10.1177/25158163211040061
- By:
- Publication type:
- Article